It's Friday already - the week has flown by - and that means it is time for our weekly links roundup.
Next week's 31st meeting of the ECTRIMS Congress will bring together MS thought leaders from the world over in Barcelona, Spain for a four-day teaching and learning meeting.
Roche released reports this week regarding the success of Ocrelizumab, the first investigational medicine to show efficacy in people with primary progressive multiple sclerosis, currently in Phase III study
In pediatric MS news, current research points to the possibility that Tysabri could be an effective option for treatment of kids with MS.
The first electronic automatic injector for β interferon in the treatment of multiple sclerosis (MS) has been approved by the US Food and Drug Administration (FDA). The autoinjector is manufactured by Bayer and delivers the company's Betaseron brand of β interferon, used to treat relapsing-remitting forms of MS. The new device, calledBetaconnect, will be available in early 2016.
We at CMSC hope that everyone going to Barcelona next week has an amazing trip filled with learning, networking with colleagues, and even a little time to see an amazing city!